与心脏毒性相关的免疫检查点抑制剂
Immune Checkpoint Inhibitors Related to Cardiotoxicity.
作者信息
Chen Ru, Zhou Min, Zhu Feng
机构信息
Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Clinic Center of Human Gene Research, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
出版信息
J Cardiovasc Dev Dis. 2022 Nov 3;9(11):378. doi: 10.3390/jcdd9110378.
Abstract
Immune checkpoint inhibitors (ICIs) have now emerged as a mainstay of treatment for various cancers. Along with development of ICIs, immune-related adverse effects (irAEs) have aroused wide attention. The cardiac irAE, one of the rare but potentially fatal effects, have been reported recently. However, the clinical comprehension of cardiac irAEs remains limited and guidelines are inadequate for cardio-oncologists to tackle the problem. In this review, we have summarized current classifications of, manifestations of, potential mechanisms of, and treatment for ICI-related myocardial injury in order to provide some clues for the understanding of cardiac irAEs in clinical work.
摘要
免疫检查点抑制剂（ICIs）现已成为多种癌症治疗的主要手段。随着ICIs的发展，免疫相关不良反应（irAEs）引起了广泛关注。心脏irAE是罕见但可能致命的不良反应之一，最近已有报道。然而，对心脏irAE的临床认识仍然有限，且指南不足以帮助心脏肿瘤学家解决这一问题。在本综述中，我们总结了ICI相关心肌损伤的当前分类、表现、潜在机制和治疗方法，以便为临床工作中理解心脏irAE提供一些线索。
相似文献
1
Immune Checkpoint Inhibitors Related to Cardiotoxicity.与心脏毒性相关的免疫检查点抑制剂
J Cardiovasc Dev Dis. 2022 Nov 3;9(11):378. doi: 10.3390/jcdd9110378.
2
Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do.免疫检查点抑制剂所致心脏毒性：心脏肿瘤团队应了解与应对的事项
Cancers (Basel). 2022 Nov 2;14(21):5403. doi: 10.3390/cancers14215403.
3
Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.癌症患者接受免疫检查点抑制剂治疗的特定免疫相关不良事件的真实世界临床和经济结局。
Oncologist. 2021 Nov;26(11):e2002-e2012. doi: 10.1002/onco.13918. Epub 2021 Aug 24.
4
Case Report: Cardiac Toxicity Associated With Immune Checkpoint Inhibitors.病例报告：与免疫检查点抑制剂相关的心脏毒性
Front Cardiovasc Med. 2021 Dec 6;8:727445. doi: 10.3389/fcvm.2021.727445. eCollection 2021.
5
Advances in immune checkpoint inhibitors induced-cardiotoxicity.免疫检查点抑制剂诱导的心脏毒性的研究进展。
Front Immunol. 2023 Feb 23;14:1130438. doi: 10.3389/fimmu.2023.1130438. eCollection 2023.
6
Cardiac Complications in Immune Checkpoint Inhibition Therapy.免疫检查点抑制疗法中的心脏并发症
Front Cardiovasc Med. 2019 Jan 23;6:3. doi: 10.3389/fcvm.2019.00003. eCollection 2019.
7
Cardiotoxicity of Immune Checkpoint Inhibitors.免疫检查点抑制剂的心脏毒性。
Curr Oncol Rep. 2021 May 3;23(7):79. doi: 10.1007/s11912-021-01070-6.
8
Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis.免疫检查点抑制剂治疗相关的心脏毒性：一项荟萃分析。
Eur J Heart Fail. 2021 Oct;23(10):1739-1747. doi: 10.1002/ejhf.2289. Epub 2021 Jul 29.
9
Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.免疫检查点抑制剂治疗转移性肾和尿路上皮癌患者的条件性免疫毒性发生率。
J Immunother Cancer. 2020 Mar;8(1). doi: 10.1136/jitc-2019-000371.
10
Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges.免疫检查点抑制剂相关的心脏毒性：现状与未来挑战。
Front Pharmacol. 2022 Aug 30;13:962596. doi: 10.3389/fphar.2022.962596. eCollection 2022.
引用本文的文献
1
Predictive Value of Neutrophil-to-Lymphocyte Ratio for Immune Checkpoint Inhibitor-Related Myocarditis Among Patients Treated for Non-Small-Cell Lung Cancer.非小细胞肺癌患者中中性粒细胞与淋巴细胞比值对免疫检查点抑制剂相关心肌炎的预测价值
Cancer Innov. 2025 Feb 20;4(2):e163. doi: 10.1002/cai2.163. eCollection 2025 Apr.
2
Early detection of myocarditis caused by immune checkpoint inhibitor therapy with nivolumab and ipilimumab for advanced recurrent renal cell carcinoma.早期检测纳武单抗和伊匹单抗免疫检查点抑制剂疗法治疗晚期复发性肾细胞癌所致的心肌炎。
Cancer Immunol Immunother. 2025 Feb 4;74(3):97. doi: 10.1007/s00262-025-03945-0.
3
Emerging Role of Circular RNAs in Hepatocellular Carcinoma Immunotherapy.环状 RNA 在肝细胞癌免疫治疗中的新兴作用。
Int J Mol Sci. 2023 Nov 18;24(22):16484. doi: 10.3390/ijms242216484.
4
BRD2 protects the rat H9C2 cardiomyocytes from hypoxia‑reoxygenation injury by targeting Nrf2/HO‑1 signaling pathway.BRD2通过靶向Nrf2/HO-1信号通路保护大鼠H9C2心肌细胞免受缺氧-复氧损伤。
Exp Ther Med. 2023 Oct 4;26(5):542. doi: 10.3892/etm.2023.12241. eCollection 2023 Nov.
5
Cardiovascular Toxicity Related to Cancer Treatment.与癌症治疗相关的心血管毒性
J Cardiovasc Dev Dis. 2023 Jun 14;10(6):259. doi: 10.3390/jcdd10060259.
本文引用的文献
1
Cardiovascular adverse events induced by immune checkpoint inhibitors: A real world study from 2018 to 2022.免疫检查点抑制剂所致心血管不良事件：一项2018年至2022年的真实世界研究。
Front Cardiovasc Med. 2022 Aug 10;9:969942. doi: 10.3389/fcvm.2022.969942. eCollection 2022.
2
Cardiovascular Outcomes and Hospitalizations in Asian Patients Receiving Immune Checkpoint Inhibitors: A Population-based Study.亚洲患者接受免疫检查点抑制剂治疗的心血管结局和住院情况：一项基于人群的研究。
Curr Probl Cardiol. 2023 Jan;48(1):101380. doi: 10.1016/j.cpcardiol.2022.101380. Epub 2022 Aug 27.
3
Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis.鉴定与检查点抑制剂诱导性心肌炎相关的致病性免疫细胞亚群。
Circulation. 2022 Jul 26;146(4):316-335. doi: 10.1161/CIRCULATIONAHA.121.056730. Epub 2022 Jun 28.
4
PD-1 Inhibitor-Induced Thyrotoxicosis Associated with Coronary Artery Spasm and Ventricular Tachycardia.PD-1 抑制剂相关的甲状腺毒症伴发冠状动脉痉挛和室性心动过速。
Cardiovasc Toxicol. 2022 Nov;22(10-11):892-897. doi: 10.1007/s12012-022-09756-4. Epub 2022 Jun 21.
5
A Systematic Review of the Mechanisms Involved in Immune Checkpoint Inhibitors Cardiotoxicity and Challenges to Improve Clinical Safety.免疫检查点抑制剂心脏毒性相关机制及改善临床安全性面临挑战的系统评价
Front Cell Dev Biol. 2022 Mar 30;10:851032. doi: 10.3389/fcell.2022.851032. eCollection 2022.
6
Patterns of Peripheral Blood B-Cell Subtypes Are Associated With Treatment Response in Patients Treated With Immune Checkpoint Inhibitors: A Prospective Longitudinal Pan-Cancer Study.外周血 B 细胞亚型模式与免疫检查点抑制剂治疗患者的治疗反应相关：一项前瞻性的泛癌种纵向研究。
Front Immunol. 2022 Apr 1;13:840207. doi: 10.3389/fimmu.2022.840207. eCollection 2022.
7
Immune Checkpoint Inhibitors-Associated Cardiotoxicity.免疫检查点抑制剂相关心脏毒性
Cancers (Basel). 2022 Feb 23;14(5):1145. doi: 10.3390/cancers14051145.
8
Rare Case of Wide QRS Tachycardia After Sintilimab Treatment for Lung Cancer.信迪利单抗治疗肺癌后出现宽QRS波心动过速的罕见病例。
Circulation. 2022 Mar 8;145(10):783-786. doi: 10.1161/CIRCULATIONAHA.121.058936. Epub 2022 Mar 7.
9
Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition.基线较低的自身抗体水平与免疫检查点抑制的免疫相关不良事件有关。
J Immunother Cancer. 2022 Jan;10(1). doi: 10.1136/jitc-2021-004008.
10
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial.舒格利单抗联合同步或序贯放化疗对比安慰剂用于中国局部晚期、不可切除、III 期非小细胞肺癌患者的 GEMSTONE-301 研究：一项随机、双盲、多中心、III 期临床研究的期中分析结果
Lancet Oncol. 2022 Feb;23(2):209-219. doi: 10.1016/S1470-2045(21)00630-6. Epub 2022 Jan 14.
Zotero 插件